ARGX ARGENX SE IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1697862 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2022Q22022-06-30 |
|---|---|
| Income statement | |
| Revenue | $96.00M |
| Net income | — |
| EPS (diluted) | — |
| Balance sheet | |
| Cash & equivalents | $1.37B |
| Receivables | $112.39M |
| Inventory | $135.71M |
| Current assets | $2.93B |
| PP&E, netmay include right-of-use assets (IFRS) | $14.24M |
| Intangibles | $171.29M |
| Total assets | $3.25B |
| Current liabilities | $264.60M |
| Total liabilities | $279.02M |
| Shareholders' equity | $2.97B |
| Shares outstanding | 55.06M |
| Cash flow statement | |
| Operating cash flow | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.